Endoscopy Surgery in India
Get Endoscopy Surgery at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Endoscopy Surgery in UAE
Endoscopy Surgery at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Endoscopic cancer surgery is a minimally invasive oncological procedure that uses advanced endoscopic platforms — including flexible endoscopy, endoscopic submucosal dissection (ESD), endoscopic mucosal resection (EMR), and natural orifice transluminal endoscopic surgery (NOTES) — to resect early-stage and select advanced gastrointestinal, pulmonary, and urological tumors with curative or palliative intent, often avoiding the need for open surgery. Reported R0 resection rates for early-stage gastrointestinal malignancies exceed 90% in high-volume centers, with complication profiles significantly lower than conventional open or laparoscopic oncological surgery. GAF Healthcare connects international patients to India's JCI- and NABH-accredited cancer centers and Dubai/Abu Dhabi's JCI- and DHA-licensed hospitals, providing end-to-end coordination so that patients from across the Middle East, Africa, CIS, and Southeast Asia receive world-class oncological endoscopy at a fraction of Western costs.
Hospital Stay: 2–5 days (varies by tumor site, resection complexity, and postoperative surveillance requirements) • Total Stay in Country (Fit-to-Fly): 1–3 weeks (short-haul flights typically cleared at 7–10 days post-procedure for uncomplicated cases; long-haul international flights generally cleared at 2–3 weeks pending oncology review and absence of post-procedural bleeding or perforation) • Success Rate: 90–95% R0 (complete margin-negative) resection rate for early-stage (T1a/T1b) gastrointestinal malignancies at high-volume accredited centers; 5-year survival for early gastric cancer treated with ESD exceeds 95%
What Is It?
Endoscopic cancer surgery encompasses a spectrum of image-guided, lumen-based or cavity-based oncological resection techniques that eliminate or minimize the need for external incisions. The primary anatomical targets include the esophagus, stomach, duodenum, colon, rectum, biliary tract, lungs (via endobronchial platforms), and urinary bladder (via transurethral resection of bladder tumor, TURBT). In gastrointestinal oncology — the dominant indication — mucosal and submucosal cancers confined to the superficial layers of the bowel wall (T1a–T1b) are addressed via endoscopic mucosal resection (EMR) or the technically superior endoscopic submucosal dissection (ESD), a technique refined in Japan and now practiced at elite centers globally. ESD achieves en-bloc resection of lesions regardless of size, enabling precise histopathological staging of lateral and vertical margins — a capability that piecemeal EMR cannot consistently deliver.
The physiological advantage of endoscopic oncological surgery over conventional open or even laparoscopic approaches is profound. Because no abdominal or thoracic wall is breached, patients experience dramatically reduced inflammatory cytokine cascades, preserve core immunological function critical for post-surgical oncological surveillance, and resume oral nutrition within 24–48 hours. Blood loss is typically less than 20 mL, general anesthesia requirements are shorter (30–90 minutes for most ESD procedures), and the absence of surgical wounds eliminates wound-related infection pathways. For patients who are elderly, medically frail, or on anticoagulation therapy for comorbid cardiovascular disease, this physiological gentleness is clinically decisive.
Standard of care for endoscopic cancer surgery at accredited centers integrates several interdependent pillars: high-definition white-light endoscopy (HD-WLE) combined with image-enhanced endoscopy (IEE) modalities such as narrow-band imaging (NBI), linked color imaging (LCI), or blue-laser imaging (BLI) for lesion characterization and boundary delineation; endoscopic ultrasound (EUS) for T- and N-staging prior to resection; multidisciplinary tumor board review involving surgical oncology, medical oncology, gastroenterology, pathology, and radiology; and standardized post-resection surveillance endoscopy protocols at 3, 6, and 12 months. Hybrid procedures — such as laparoscopic-assisted endoscopic surgery (LAES) or endoscopic full-thickness resection (EFTR) for select submucosal tumors — extend the oncological reach of the endoscopic platform into cases previously requiring open resection.
Candidates
• ELIGIBLE PATIENTS:
• Patients with early-stage esophageal cancer: high-grade dysplasia (HGD) in Barrett's esophagus, squamous cell carcinoma confined to mucosa (T1a) or select T1b lesions with low-risk histology
• Patients with early gastric cancer (EGC): well-differentiated adenocarcinoma ≤2 cm without ulceration (absolute ESD criteria) or expanded criteria lesions per Japanese Gastric Cancer Association (JGCA) guidelines
• Colorectal lesions: large (>20 mm) non-pedunculated polyps (laterally spreading tumors, LSTs), T1 colorectal cancers with sm1 submucosal invasion, rectal tumors amenable to transanal endoscopic microsurgery (TEM) or transanal minimally invasive surgery (TAMIS)
• Non-muscle-invasive bladder cancer (NMIBC): eligible for TURBT with or without en-bloc resection technique; restaging TURBT for high-grade T1 disease
• Early-stage ampullary and duodenal adenomas or carcinomas: amenable to endoscopic papillectomy or duodenal ESD
• Endobronchial tumors: central airway tumors causing obstruction, amenable to bronchoscopic resection, laser ablation, or cryotherapy
• Biliary tract: select intraductal papillary neoplasms via SpyGlass cholangioscopy-guided resection
• REQUIRED PRE-PROCEDURAL DIAGNOSTICS:
• High-definition endoscopy with IEE (NBI/LCI) for lesion characterization and pit pattern analysis (Kudo/JNET classification)
• Endoscopic ultrasound (EUS) with or without fine-needle aspiration (FNA/FNB) for locoregional T/N staging
• PET-CT (18F-FDG) to exclude distant metastatic disease before curative-intent resection
• CT scan of chest, abdomen, and pelvis with IV contrast for anatomical staging
• MRI pelvis for rectal tumors; MRI liver for hepatic extension assessment in biliary cases
• Complete blood count (CBC), coagulation profile (PT/INR, aPTT), liver function tests (LFTs), renal function tests (RFTs), serum albumin (nutritional status)
• Tumor markers: CEA, CA 19-9 (colorectal/biliary); CA 72-4, CA 125 (gastric); AFP (if hepatocellular involvement suspected)
• Cardiopulmonary evaluation: ECG, echocardiogram (ECHO), pulmonary function tests (PFTs) for patients with significant cardiorespiratory comorbidities; anesthesiology-guided ASA physical status classification
• Helicobacter pylori testing (urea breath test or stool antigen) mandatory for all gastric cancer candidates; eradication therapy required pre-ESD
• CONTRAINDICATIONS:
• Advanced T-stage disease (T2 or deeper invasion confirmed on EUS or MRI) requiring radical surgical oncological resection with lymphadenectomy
• Presence of lymph node metastases (N+) confirmed on imaging or EUS-FNA
• Distant metastatic disease (M1) — endoscopic resection non-curative in this setting (palliative endoscopic procedures such as stenting may still apply)
• Uncorrectable coagulopathy (INR >2.5 that cannot be reversed; platelet count <50,000/μL)
• Active anticoagulation with inability to safely bridge or discontinue therapy
• Lesion morphology unfavorable for en-bloc endoscopic resection (e.g., severe fibrosis from prior injection, radiation-induced changes, or deep sm3 invasion)
• Medically unstable patients with decompensated cardiac or respiratory failure (ASA Class IV–V for procedural sedation)
• Prior local treatment (radiation, EMR) causing significant submucosal fibrosis at the lesion site — relative contraindication requiring expert endoscopist assessment
Procedure
STANDARD ENDOSCOPIC APPROACHES:
• Endoscopic Mucosal Resection (EMR): The foundational technique for resecting mucosal lesions ≤20 mm. A submucosal injection of saline or viscous solution (hydroxypropyl methylcellulose, hyaluronic acid) creates a cushion lifting the lesion, which is then captured with a snare and resected using electrocautery. EMR is fast and widely available but limited by piecemeal resection for larger lesions, increasing local recurrence rates to 10–20% for lesions >20 mm. Indicated for flat adenomas, low-risk T1a lesions, and as a staging procedure.
• Endoscopic Submucosal Dissection (ESD): The gold standard for curative endoscopic oncological resection. Following submucosal injection, the endoscopist uses purpose-built electrosurgical knives (Dual knife, IT knife, Hook knife, Flush knife) to systematically dissect the submucosal plane, achieving en-bloc resection of lesions of any size. Procedure duration: 45 minutes to 4+ hours depending on lesion size and fibrosis. En-bloc resection rates exceed 95% in expert hands, with curative resection (R0, absence of lymphovascular invasion, appropriate depth criteria) achieved in 80–90% of cases. Now considered standard of care for gastric EGC, esophageal ESD, and large colorectal LSTs at centers meeting JGES/ESGE volume thresholds.
ADVANCED & HYBRID APPROACHES:
• Endoscopic Full-Thickness Resection (EFTR): Performed with the over-the-scope clip-based FTRD (Full-Thickness Resection Device) system, EFTR resects lesions including all bowel wall layers, targeting difficult non-lifting polyps, recurrent adenomas, and T1 colorectal cancers with sm involvement. Avoids laparoscopic surgery in select patients. Particularly useful for appendiceal orifice lesions and submucosal tumors (GISTs ≤2 cm).
• Transanal Endoscopic Microsurgery (TEM) / Transanal Minimally Invasive Surgery (TAMIS): Platforms for full-thickness local excision of select rectal tumors (T1 N0, <3 cm, within 15 cm of anal verge). TAMIS uses standard laparoscopic instruments through a single-port transanal platform (GelPOINT Path), while TEM uses a dedicated rigid rectoscope with integrated optics. Both achieve precise full-thickness excision under direct vision with suture closure, offering an organ-preserving alternative to total mesorectal excision (TME) for highly selected low-risk rectal cancers.
• Submucosal Tunneling Endoscopic Resection (STER): Used for resection of subepithelial tumors (SETs) — including GISTs and leiomyomas — in the esophagus and gastric cardia. A submucosal tunnel is created proximal to the lesion, the tumor is dissected and extracted through the tunnel, and the mucosal entry is closed with clips. Preserves mucosal integrity and avoids full-thickness perforation risk.
• Natural Orifice Transluminal Endoscopic Surgery (NOTES): An emerging platform where the peritoneal or pleural cavity is accessed entirely via natural orifices (transoral, transgastric, transcolonic). Pure NOTES remains investigational for most oncological indications but transvaginal and transgastric hybrid-NOTES approaches are performed at specialized centers for cholecystectomy and select peritoneal staging procedures.
• Endobronchial Interventional Oncology: For central airway tumors, a suite of bronchoscopic techniques is deployed: rigid bronchoscopy with mechanical debulking, Nd:YAG or diode laser tumor ablation, argon plasma coagulation (APC), cryotherapy (tumor debulking and tissue retrieval), photodynamic therapy (PDT) for superficial endobronchial carcinoma-in-situ, and bronchoscopic brachytherapy. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) provides concurrent nodal staging.
• En-bloc TURBT with Bipolar Energy / Laser: For bladder cancer, en-bloc TURBT using a dedicated resection loop or thulium/holmium laser achieves true pathological specimens with intact detrusor muscle for accurate T-staging, reducing the need for restaging TURBT and improving oncological outcomes compared to conventional piecemeal TURBT.
• Technological Adjuncts Across Platforms: Confocal laser endomicroscopy (CLE) for real-time in-vivo histology; artificial intelligence (AI)-assisted polyp detection and characterization systems (CADe/CADx); fluorescence imaging with indocyanine green (ICG) for sentinel node mapping during endoscopic-laparoscopic hybrid procedures; and next-generation endoscopes with 4K ultra-high-definition optics and robotically-assisted flexible endoscopy platforms (e.g., Flex Robotic System for endoluminal surgery).
Cost of Endoscopy Surgery: India vs. UAE
The cost of endoscopic cancer surgery varies significantly depending on the tumor site, endoscopic platform employed (EMR versus complex ESD or TAMIS), anesthesia type, hospital tier, and the extent of pre-procedural workup required. India offers highly competitive pricing — typically 40–60% lower than the UAE — without compromising on endoscopic expertise or accreditation standards, making it the preferred destination for cost-sensitive patients from Africa, South Asia, and the CIS region. The UAE, with its premium hospital infrastructure, multilingual clinical teams, and near visa-free accessibility for many nationalities, attracts patients prioritizing luxury recovery environments, shorter travel distances from the GCC region, and proximity to home for rapid return if complications arise. Both destinations offer JCI-accredited institutions with internationally trained gastroenterological oncologists and dedicated endoscopy suites equipped with Olympus, Fujifilm, and Pentax latest-generation endoscopy systems.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $2,500 – $9,000 | ~52% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $6,000 – $18,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PRE-PROCEDURE PHASE (Days -14 to -1):
• Day -14 to -7: GAF Healthcare coordinates remote medical record review by a designated specialist (gastroenterological oncologist or interventional endoscopist) at the receiving hospital. Existing imaging (CT, PET-CT, prior endoscopy reports) and histopathology are reviewed. A formal second-opinion report is issued and treatment candidacy confirmed.
• Day -7 to -3: Patient travels to India or UAE. GAF Healthcare airport transfer team receives patient and attendant. Check-in at pre-arranged hospital-adjacent accommodation or hospital-affiliated guest house.
• Day -5 to -2 (Pre-admission workup): Outpatient visit to the hospital for repeat endoscopy with IEE characterization and EUS staging if not already performed to international standards. Blood investigations, ECG, ECHO, anesthesiology consultation, and nutritional assessment. Helicobacter pylori eradication status confirmed. Informed consent obtained with dedicated interpreter if required.
• Day -1: Bowel preparation for colorectal procedures (polyethylene glycol or sodium picosulfate-based prep per center protocol). Nil by mouth (NBM) from midnight. Anticoagulation bridging protocol executed per hematology guidance. Admission to hospital room.
PROCEDURE DAY (Day 0):
• Patient transferred to endoscopy suite or hybrid operating theater. Anesthesiology team establishes monitored anesthesia care (MAC) with deep propofol sedation or general anesthesia with endotracheal intubation, selected based on expected procedure duration, patient comorbidities, and tumor location.
• Procedure duration: 30 minutes (uncomplicated EMR/TURBT) to 3–5 hours (complex ESD with significant fibrosis or large rectal TAMIS). Real-time endoscopic monitoring including cardiopulmonary vital signs, CO2 insufflation to minimize gas-related complications.
• Immediate post-procedure: Recovery room observation for 2–4 hours. Vital signs, abdominal/chest assessment, and hemodynamic stability confirmed. Nil by mouth maintained for 6–12 hours post-ESD; clear liquids cautiously introduced.
• Resected specimen submitted for urgent histopathological processing: lesion size, depth of invasion (T-stage), lateral and vertical margin status (R0/R1), lymphovascular invasion (LVI), perineural invasion, and differentiation grade.
POST-PROCEDURE HOSPITAL PHASE (Days 1–5):
• Day 1: Clear liquid diet advanced (ESD/EMR). TURBT patients typically mobilize within hours and may be discharged Day 1–2 with catheter in situ. Endobronchial procedure patients observed for pneumothorax/hemoptysis on chest X-ray.
• Day 2–3: Full histopathology report reviewed at multidisciplinary tumor board. Soft diet commenced for gastric/esophageal ESD patients. IV PPI (proton pump inhibitor) converted to high-dose oral PPI. Absence of bleeding or perforation on clinical review.
• Day 3–5: Discharge criteria assessed — hemodynamic stability, adequate oral intake, no fever, no peritoneal signs, satisfactory serial blood counts. Patient discharged to recovery accommodation.
POST-DISCHARGE RECOVERY PHASE (Days 5–21, pre-flight):
• Days 5–10: Outpatient follow-up endoscopy may be performed at Day 7 for complex ESD cases to confirm ulcer healing and absence of delayed bleeding (incidence: 3–5%). Soft to regular diet progression. Abstinence from NSAIDs and anticoagulants per protocol duration.
• Day 10–14: Oncology review with finalized histopathology. If curative resection confirmed (R0, no high-risk features), no immediate additional surgery required. If non-curative features identified (positive vertical margin, LVI, sm2–3 invasion), discussion of additional surgical options or adjuvant therapy initiated — this may extend country stay.
• Day 14–21: Fit-to-fly assessment by treating physician. Short-haul flights (<4 hours) typically cleared at Day 7–10 for uncomplicated cases. Long-haul international flights cleared at Day 14–21, contingent on absence of delayed complications, adequate nutritional status, and confirmed wound/ulcer healing on follow-up endoscopy.
LONG-TERM FOLLOW-UP (Post-departure):
• Surveillance endoscopy protocol: 3 months, 6 months, 12 months, then annually for 5 years per ESGE/JGES guidelines. GAF Healthcare facilitates telemedicine follow-up consultations and coordinates with the patient's local oncologist for ongoing surveillance. Digital pathology reports and procedure documentation transmitted securely to the patient's home-country physician.
Risks & Considerations
Endoscopic cancer surgery carries a significantly lower overall risk profile than open or laparoscopic oncological surgery, but procedure-specific complications are well-documented and must be transparently disclosed to traveling patients. The two most clinically significant acute complications are intraprocedural perforation (incidence: 1–5% for ESD, higher for colonic vs. gastric sites) and delayed bleeding (3–7% for gastric ESD, 1–3% for esophageal ESD). Perforation is typically managed endoscopically with through-the-scope clips or over-the-scope clips (OTSC) in experienced hands, avoiding emergency surgery in the majority of cases; however, uncontrolled perforation may necessitate urgent laparoscopic or open surgical repair — a scenario that would extend hospital stay and delay the patient's ability to fly home. Delayed bleeding most commonly occurs between Days 4 and 14 post-procedure and typically presents as hematemesis or hematochezia, requiring urgent endoscopic hemostasis and potentially blood transfusion. Patients on anticoagulation or antiplatelet therapy carry significantly elevated bleeding risk, and bridging protocols must be precisely executed. Stricture formation at the esophageal resection site occurs in up to 30–40% of cases following circumferential or near-circumferential esophageal ESD and requires post-procedural endoscopic dilation sessions, which may necessitate additional outpatient visits before the patient is safely cleared for international travel. For TURBT, risks include hbladder wall perforation (1–5%), obturator nerve reflex-related lateral bladder perforation (mitigated by neuromuscular blockade during general anesthesia), urinary tract infection, and urethral stricture. For endobronchial procedures, pneumothorax, significant hemoptysis, and bronchopleural fistula are rare but serious risks. From an oncological standpoint, the critical risk for international patients is non-curative resection (R1 margins or high-risk histological features identified post-procedure), which necessitates further oncological discussion — either additional endoscopic or surgical resection — potentially requiring an extended stay or a return trip. GAF Healthcare strongly advises all patients to maintain travel insurance covering medical repatriation and to build flexibility into their return travel plans for a minimum of 3 weeks post-procedure.
Top Hospitals for Endoscopy Surgery
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Endoscopy Surgery
Internationally trained specialists in Surgical Oncology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Ashwin Sunil Tamhankar
MBBS, MS, MCh Urology, DNB Urology, Vattikuti Robotic Uro-oncology Fellowship, RCS Laser Urological Robotic Fellowship, Olympus Laparoscopic Endo-Urology Fellowship
Surgical Oncologist & Robotic Uro-Oncologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Ashwin Sunil Tamhankar is a Consultant in Surgical Oncology and Robotic Surgery based at Apollo Hospitals in Navi Mumbai, India. With over 9 years of specialized experience, he has established himself as a leading uro-oncologist, combining advanced robotic surgical techniques with precision cancer care. His credentials include MBBS, MS, MCh Urology, DNB Urology, and prestigious fellowships from the Vattikuti Institute, Royal College of Surgeons of… Read more
Dr. Asit Arora
MBBS, MS, MCh
GI & HPB Surgical Oncologist
Indraprastha Apollo Hospital, New Delhi, India
22+ Yearsof experience
Dr. Asit Arora is a Clinical Lead in GI and HPB Surgical Oncology at Indraprastha Apollo Hospital, New Delhi, bringing over 22 years of specialized expertise in managing complex gastrointestinal and hepatobiliary cancers. He holds an MBBS, MS in General Surgery, and an MCh in Gastrointestinal Surgery, and is widely recognized across India and internationally for his precision in radical oncologic resections and advanced abdominal cancer surgery. Dr. Arora… Read more
Dr. B. Niranjan Naik
MBBS, MS, Onco-Surgery, FIAGES
Surgical Oncologist
Paras Hospitals, Gurugram, India
22+ Yearsof experience
Dr. B. Niranjan Naik is Principal Director of Surgical Oncology and Director of Breast & Gastro-Intestinal Onco-Surgery at Paras Hospitals in Gurugram. With over 22 years of distinguished clinical experience, he is widely recognized as one of the leading breast cancer surgeons in the Delhi and Gurugram region. His credentials include MBBS and MS (General Surgery) from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by specialized… Read more
Dr. Belal Bin Asaf
MBBS, MS (Surgery), Fellowship in Thoracic Surgery, Certification as Robotic Console Surgeon, Observing Fellowship in VATS Lobectomy, Training in Minimally Invasive Esophagectomy
Thoracic Surgical Oncologist
Medanta — The Medicity, Gurugram, India
20+ Yearsof experience
Dr. Belal Bin Asaf is a distinguished Thoracic Surgical Oncologist and Director of Surgical Oncology at Medanta — The Medicity in Gurugram. With over 20 years of clinical experience, he has established himself as a pioneering leader in minimally invasive thoracic surgical oncology across India. His credentials include MBBS, MS in Surgery, Fellowship in Thoracic Surgery, and specialized certification as a Robotic Console Surgeon, combined with focused… Read more
Frequently Asked Questions — Endoscopy Surgery
The total cost of endoscopic cancer surgery depends heavily on the specific procedure (EMR, ESD, TAMIS, TURBT, or endobronchial resection), tumor site, complexity, hospital tier, and the extent of pre-procedural staging workup required. In India, at JCI- and NABH-accredited oncology centers, the all-inclusive cost — covering specialist fees, procedure room charges, anesthesiology, hospital stay of 2–5 days, standard post-procedural medications (IV PPI, hemostatics), and nursing care — typically ranges from USD 2,500 to USD 9,000. Complex procedures such as large colorectal ESD with EFTR or TAMIS for rectal cancer fall toward the upper end of this range. In the UAE (Dubai or Abu Dhabi), at JCI-accredited hospitals operating under DHA or DoH licensure, equivalent procedures cost between USD 6,000 and USD 18,000, reflecting premium infrastructure, international specialist compensation structures, and the higher cost-of-living environment. In both cases, PET-CT, EUS, and MRI staging (if not already performed) add USD 500–2,000 to total costs. India typically represents a 40–60% cost saving versus the UAE for identical procedures. GAF Healthcare provides itemized cost estimates specific to your diagnosis and imaging prior to travel commitment, with no hidden charges.
The fit-to-fly timeline after endoscopic cancer surgery is not uniform and depends on three key variables: the procedure performed, the occurrence of any post-procedural complications, and the duration of your return flight. For uncomplicated EMR or TURBT, patients are typically cleared for short-haul flights (under 4 hours) within 5–7 days of the procedure. For endoscopic submucosal dissection (ESD) — especially gastric, esophageal, or colonic ESD — the minimum recommended in-country stay is 10–14 days, as delayed bleeding (the most common serious complication) typically occurs within the first 14 days. For TAMIS or TEM rectal resection, a 14–21 day stay is advisable, with a follow-up wound/anastomosis assessment before travel clearance. Long-haul international flights (over 6–8 hours) carry additional risks including dehydration, deep vein thrombosis (DVT), and limited access to emergency medical care; treating physicians at GAF Healthcare's partner hospitals will not clear patients for long-haul travel until clinical, endoscopic, and laboratory parameters confirm healing. If curative resection cannot be confirmed immediately (non-curative histology requiring tumor board deliberation and possible additional intervention), country stay may be extended by 1–2 weeks. GAF Healthcare's Patient Coordinators monitor each patient's recovery milestones daily and update flight clearance status in real time, allowing attendants to rebook flights with maximum flexibility.
Success rates for endoscopic cancer surgery are highly site- and stage-specific, and must be understood through multiple distinct oncological endpoints. For early-stage gastrointestinal cancers — the primary indication — en-bloc resection rates achieved via ESD at high-volume centers exceed 95%, with curative (R0, histologically complete margin-negative) resection rates of 85–92% for gastric EGC and 80–90% for colorectal T1 lesions meeting expanded criteria. For early-stage gastric cancer treated curatively with ESD, 5-year overall survival exceeds 95%, equivalent to surgical gastrectomy with lymphadenectomy, without the morbidity of abdominal surgery. For esophageal squamous cell carcinoma confined to the mucosa (T1a), ESD achieves curative resection in over 85% of cases with 5-year disease-specific survival rates exceeding 90% at expert centers. For non-muscle-invasive bladder cancer (NMIBC, Ta/T1) treated with en-bloc TURBT using modern laser or bipolar energy platforms, recurrence-free survival at 12 months ranges from 70–85% depending on tumor grade, with restaging TURBT for high-grade T1 disease adding staging precision that reduces inappropriate understaging. For endobronchial carcinoma-in-situ treated with photodynamic therapy (PDT), complete response rates of 70–90% are reported for lesions under 1 cm. It is critical to note that 'success' in endoscopic cancer surgery refers first to complete local tumor eradication (R0 resection), second to avoidance of surgical morbidity, and third to long-term cancer-free survival under structured surveillance — all three of which are optimized when the procedure is performed by an endoscopist meeting international volume thresholds (minimum 30 gastric ESD cases per year per ESGE guidelines) at an accredited center, exactly the standard GAF Healthcare applies in vetting its partner institutions.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end logistics management for international patients traveling to India or the UAE for endoscopic cancer surgery, ensuring that no aspect of the medical journey is left to chance.
INDIA LOGISTICS:
• e-Medical Visa: GAF Healthcare's dedicated visa coordination team assists patients and up to two attendants in applying for India's e-Medical Visa (eMV), which permits a stay of up to 60 days (extendable) and allows multiple entries. Application is completed online via India's official visa portal; patients require a recommendation letter from the receiving hospital, which GAF Healthcare procures directly. Visa approval typically takes 3–5 business days. GAF Healthcare tracks application status and provides a dedicated point-of-contact for embassy-related queries.
• Airport Reception: Dedicated multilingual GAF Healthcare ground staff receive patients at major international airports (IGI Delhi, CSIA Mumbai, RGIA Hyderabad, KIAL Bangalore) with pre-arranged private vehicle transfers directly to the hospital or affiliated accommodation.
• Accommodation: GAF Healthcare has pre-negotiated rates at hospital guesthouses and service apartments within 2 km of partner hospitals for patient attendants. Dietary preferences (halal, kosher, vegetarian) are confirmed in advance.
• Translation Services: Arabic, Russian, French, Swahili, and Amharic medical interpreters are coordinated for in-clinic consultations and consent procedures. All medical documents are translated and certified for immigration purposes on request.
UAE LOGISTICS:
• Visa Access: Citizens of 120+ countries enjoy visa-on-arrival or visa-free access to the UAE (Dubai/Abu Dhabi). GAF Healthcare provides a detailed eligibility guide and, where prior visa approval is required, coordinates with UAE health tourism facilitators licensed under Dubai Health Authority (DHA) or Department of Health Abu Dhabi (DoH) to facilitate medical entry permits.
• Hospital Coordination: GAF Healthcare's UAE partner hospitals include JCI-accredited institutions operating under DHA licensure in Dubai and DoH licensure in Abu Dhabi. A dedicated international patient services (IPS) desk at each partner hospital provides in-hospital concierge support, insurance pre-authorization (for patients with international health coverage), and billing transparency.
• Ground Transport: Luxury vehicle airport transfers (Dubai International/Abu Dhabi International) and inter-hospital transport for second opinions or multi-specialty consultations are coordinated by GAF Healthcare.
• Accommodation: Four- and five-star hotels with medical proximity, hospital-adjacent serviced apartments, and hospital-affiliated recovery suites are available at negotiated rates. Room configuration for accompanying family members is confirmed at booking.
CROSS-DESTINATION SERVICES (India & UAE):
• A single dedicated GAF Healthcare Patient Coordinator (reachable 24/7 via WhatsApp, email, and phone) manages the entire journey from initial inquiry to post-discharge clearance.
• Digital medical record management: all reports, imaging CDs, histopathology slides, and discharge summaries are digitized and uploaded to a secure patient portal accessible by the patient and their home-country physician.
• Insurance and billing support: GAF Healthcare assists with international health insurance pre-authorization, cost estimates for insurer submission, and itemized billing documentation.
• Telemedicine follow-up: Post-departure, patients are enrolled in a structured telemedicine surveillance program connecting them with their treating endoscopic oncologist at scheduled intervals aligned with the post-procedural surveillance protocol.
Patients Also Explore
Other treatments commonly sought by patients considering Endoscopy Surgery.
Breast Cancer Treatment
Cancer Care
Lung Cancer Treatment
Cancer Care
Colonoscopy & Polypectomy
Gastroenterology
Hepatitis B Treatment
Gastroenterology